Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.

Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.

ML-SA5 is a potent agonist of TRPML1 cation channel that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC50 of 285 nM and exhibit anticancer activity.

Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.

Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.